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Antipsychotic drugs have thus far focused on dopaminergic antagonism at the D2 recep-
tors, as counteracting the hyperdopaminergia in nigrostriatal and mesolimbic projections
has been considered mandatory for the antipsychotic action of the drugs. Current drugs
effectively target the positive symptoms of psychosis such as hallucinations and delusions
in the majority of patients, whereas effect sizes are smaller for negative symptoms and
cognitive dysfunctions. With the understanding that neurocognitive dysfunction associ-
ated with schizophrenia have a greater impact on functional outcome than the positive
symptoms, the focus in pharmacotherapy for schizophrenia has shifted to the potential
effect of future drugs on cognitive enhancement. A major obstacle is, however, that the
biological underpinnings of cognitive dysfunction remain largely unknown. With the avail-
ability of increasingly sophisticated techniques in molecular biology and brain imaging,
this situation is about to change with major advances being made in identifying the neu-
ronal substrates underlying schizophrenia, and putative pro-cognitive drug targets may be
revealed. In relation to cognitive effects, this review focuses on evidence from basic neu-
roscience and clinical studies, taking two separate perspectives. One perspective is the
identification of previously under-recognized treatment targets for existing antipsychotic
drugs, including myelination and mediators of inflammation. A second perspective is the
development of new drugs or novel treatment targets for well-known drugs, which act on
recently discovered treatment targets for cognitive enhancement, and which may comple-
ment the existing drugs. This might pave the way for personalized treatment regimens for
patients with schizophrenia aimed at improved functional outcome.The review also aims at
identifying major current constraints for pro-cognitive drug development for patients with
schizophrenia.
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INTRODUCTION
Schizophrenia is a severe mental disorder with typical onset in the
late teens or early adulthood and a chronically relapsing remitting
course in the majority of cases (1). Schizophrenia remains a lead-
ing cause of years lived with disability (2), and active psychosis has
been ranked among the most disabling disorders by severity in the
general population (3).
The clinical picture of schizophrenia is heterogeneous, but in
the vast majority of patients, cognitive dysfunctions are present
with adverse impact on daily functioning (1). Antipsychotic drugs
have for six decades been a cornerstone in the treatment of the
disorder but a fundamental limitation is their small effect sizes
in the cognitive symptom domain (4) as the drugs are primar-
ily effective against the positive symptoms of psychosis including
hallucinations and delusions (4). Since the serendipitous discov-
ery of chlorpromazine’s antipsychotic properties, dopaminergic
antagonism has served as a template for all subsequent antipsy-
chotics through counteracting subcortical hyperdopaminergia (5).
The drugs following chlorpromazine are usually classified as typi-
cal or first generation antipsychotics (FGAs), whereas clozapine
much later became the prototype for the atypical or second-
generation antipsychotic (SGA) drugs that were developed in the
1990s onward (4, 6). Only modest differences in antipsychotic effi-
cacy have been found among FGAs and SGAs (7), but the SGAs
seem to display a broader therapeutic repertoire including also
pro-cognitive properties, although of a small magnitude (8). Phar-
macologically, the FGAs have strong affinities for the dopamine
type 2 (D2) receptor, whereas the SGAs are characterized by a
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more pronounced 5-HT2A antagonism than FGAs, and a lower
potency for the D2 receptor (9, 10). The narrow focus on the
dopaminergic system and striatal hyperdopaminergia in partic-
ular has most likely contributed to the limited evolvement of
more effective drug treatment options as it has become increas-
ingly clear that dopaminergic disturbances account for only parts
of the clinical picture (particularly for positive symptoms) (11–
13), and hyperdopaminergia is not present in all schizophrenia
patients (14).
Recognizing the large impact that the schizophrenia associ-
ated cognitive dysfunctions have on functional outcome (15, 16),
the efforts to improve the pharmacological treatment have moved
toward cognitive enhancement, and pro-cognitive effects have
been proposed as primary targets in future drug studies (17, 18).
A major obstacle restricting hypothesis-driven pro-cognitive drug
development has been the lacking knowledge of the structural
and functional brain alterations underlying cognitive dysfunction
in patients with schizophrenia (19, 20). Major scientific advances
in unveiling the neurobiology of schizophrenia have emerged in
recent years, however. The knowledge of transmitter dysfunc-
tions especially is widened (21), accompanied by evidence of
disturbances of myelination and inflammation/immunology in
the pathophysiology of schizophrenia (22, 23). Thus, going beyond
the neurotransmitter disturbances associated with schizophrenia,
the present work reviews the latest evidence on myelin alter-
ations, and the involvement of neuroinflammation/immunology
in schizophrenia, with putative relevance for pro-cognitive drug
effects in schizophrenia and related psychotic disorders. More-
over, these areas seem at least partly inter-related and the review
aims at integrating the evidence from key publications in a
joint model. Increased insight into the relevant functional and
structural alterations might pave the way for more efficacious,
targeted, and personalized pro-cognitive drug treatment oppor-
tunities aimed at improving real-world functioning. The review
focuses on both previously unknown treatment targets for exist-
ing antipsychotic drugs, and potentially novel pro-cognitive drugs
addressing extra-dopaminergic treatment targets, and gives an
update also commenting on current constraints of pro-cognitive
drug development for patients with schizophrenia.
COGNITIVE DYSFUNCTION IN PATIENTS WITH
SCHIZOPHRENIA
Cognitive function may be understood in terms of inter-related
complex neural networks, influenced by different neurotrans-
mitters, cytokines, and other substances including brain-derived
neurotropic factor (BDNF) acting as neuromodulators (24).
Cognitive deficits are viewed as core characteristics of schizo-
phrenia, with clinically significant cognitive impairments observed
in a large majority of patients, and most patients experience lower
cognitive functioning than would be expected from parental lev-
els of education (16, 25). Cognitive deficits are seen before the
development of psychosis (25–28), and cognitive decline and
intellectual stagnation have been suggested to constitute a risk
phenotype for developing schizophrenia (25). Furthermore, cog-
nitive deficits are relatively stable after psychotic breakthrough and
still present when the symptoms of psychosis have been treated
(29, 30). A general cognitive dysfunction across cognitive domains
is present, with additional selective deficits in working memory,
executive function, attention, verbal fluency, episodic memory,
and processing speed (15, 31). The effect size of the cognitive dys-
function compared to healthy subjects is close to 1.0 (32, 33), and
in several neurocognitive dimensions the impairment is between
1 and 2 SDs, indicating a clinically significant loss of function
(25, 34–37). Cognitive functioning has greater impact than pos-
itive psychotic symptoms in determining the patient’s real-world
functional outcome (15, 38–41), and relationships between more
specific cognitive domains and functional domains have also been
reported (38, 40, 42). Thus, cognitive impairment has been put
forward as the main target for novel treatment interventions in
schizophrenia (25).
A significant challenge has been to develop clinical meaningful
measures of cognitive dysfunction for pro-cognitive drug advance-
ment. A major contribution to establish a standardized and man-
ageable test battery for measuring cognition in schizophrenia
has been the development of the Measurement and Treatment
Research to Improve Cognition in Schizophrenia (MATRICS)
Consensus Cognitive Battery (MCCB) (43). The MCCB compos-
ite score has been suggested as the best outcome measure based
on findings of low practice effects, high test–retest reliability, and
good external validity (44), while a recent factor analysis identi-
fied a three factor model of processing speed, attention/working
memory, and learning as the best representations of data in this
particular study (45).
DOES ABNORMAL MYELINATION CAUSE COGNITIVE
DYSFUNCTIONS IN PATIENTS WITH SCHIZOPHRENIA?
Myelin, the main constituent of white matter, is essential for con-
trolling and regulating conduction velocities along axons and
thus the synchronicity of brain signals across different brain
regions, and for controlling synapse plasticity (46). Decreased
myelin integrity might accordingly alter normal signal trans-
duction. In the following, we will focus on one major line of
recent achievements in schizophrenia research, namely the rapidly
expanding knowledge of abnormal central nervous myelination
in patients with schizophrenia and the possibilities to prevent or
repair myelin pathology. White matter brain alterations and func-
tional connectivity problems that have been linked to cognitive
dysfunctions in schizophrenia will be briefly described, followed
by in-depth descriptions of new findings of myelin alterations
linked to cognition. Again, a major problem is to identify man-
ageable tests/measures of myelinization and myelin integrity that
can be used in drug discovery programs in a reliable way. Finally,
we will discuss candidate drug treatments counteracting deficits
of myelinization in patients with schizophrenia
WHITE MATTER CHANGES AND COGNITION
Several distinct alterations in gray and white matter are well
established for schizophrenia patients as a group (47). Reviews
of white matter tract pathology in patients with schizophrenia
[mostly studies based on voxel-based morphometry (VBM) and
diffusion tensor imaging (DTI)] have identified widespread and,
in many studies, progressive changes (47). A meta-analysis of
15 DTI studies by Ellison-Wright and Bullmore (48) identified
reductions (in all studies) of left frontal deep white matter and
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left temporal white matter. Thus, the authors suggested that two
different networks may be affected; one connecting the frontal
lobe with thalamus and cingulate gyrus, the other connecting the
temporal lobe with, e.g., insula, amygdala, hippocampus, and the
frontal lobe. A review by Walterfang et al. (49) of white mat-
ter pathology in patients with schizophrenia identified changes
in the left uncinate fasciculi as the most replicated finding, fur-
thermore that deficits of information processing was associated
with volume reductions in the uncinate and inferior longitudi-
nal fasciculi, anterior internal capsule, and corpus callosum (49).
White matter pathology related to cognition has also been found
in first-episode patients with psychosis. For example, Rigucci and
colleagues (50) reported a relationship between speed of process-
ing and visual memory and white matter fractional anisotropy
(FA) in fronto-temporal tracts. Focusing on intra-cortical white
matter, several clusters of superficial white matter (SWM) com-
posed of U-shaped fibers connecting neighboring gyri together
with intra-cortical axons and fibers from deep matter pathways
displayed reduced FA in a study comparing patients with schiz-
ophrenia to healthy controls. The correlations between SWM-
FA and cognition displayed in healthy controls were missing in
patients (51).
FUNCTIONAL CONNECTIVITY STUDIES
Recently, also related to myelination, the search for brain alter-
ations underlying the psychopathology of schizophrenia has refo-
cused to examine neuronal dysconnectivity, i.e., abnormal com-
munication between local and distributed neuronal circuits or
disrupted integration of brain activation (52–54). Fornito et al.
(53) reviewed data on brain connectivity, and concluded that
schizophrenia is associated with: (1) a widespread and possibly
context-independent connectivity deficits, (2) additional transient
states of hyper- and/or hypo-connectivity related to specific tasks.
Disturbed connectivity within the frontal lobes has been found
to be related to working memory and to executive functioning
(52, 54). This includes abnormal connectivity in fronto-parietal,
fronto-cerebellar, and fronto-hippocampal networks (52). Verbal
processing deficits have been shown to be related to circuits in
the language areas of the brain, particularly to fronto-temporal
dysfunction (52, 54). Indeed, theories have been developed con-
centrating on the effect of reduced executive cognitive control over
the language processing in the temporal lobes as central to the
development of the symptoms of psychosis, for instance auditory
verbal hallucination (55).
Of future interest may be the influence of antipsychotic drugs
on the dynamic interaction between large-scale cortical networks
related to resting and effort-mode states (56). Using fMRI, Hug-
dahl et al. (57) found overlapping activation in a large-scale net-
work to occur with a range of different cognitive tasks implicating
the prefrontal cortex [see also Ref. (58)] suggesting that effec-
tive cognitive processing would require down-regulation of the
resting-state network in situations with increasing demands for
the up-regulation of the effort-mode network, and that cognitive
impairment in schizophrenia may result from failure of network
up- and down-regulation dynamics. Thus, based on brain imaging
results, therapeutic agents inducing stabilization and, ideally, nor-
malization of large-scale cortical network dynamics could possibly
have pro-cognitive effects. However, thus far no drug has been
reported to enhance connectivity (52).
The major question related to the structural basis of functional
dysconnectivity was addressed in the review by Fornito et al. (53).
The authors concluded with major overlaps between functional
and structural findings, but also differences, which could at least
partly be caused by intrinsic problems of the methods of structural
measurements (see Measuring Myelination).
MEASURING MYELINATION
Several methodological issues need consideration regarding the
use of imaging techniques for myelin assessments. The DTI signal
may reveal changes in white matter integrity but has limitations
in identifying the exact nature of these changes, as the FA reflects
different processes like demyelination, axonal swelling, or atro-
phy, and is sensitive to confounding effects of fiber crossings (59).
In a recent review by Du and Öngür (60), two novel MR-based
approaches – diffusion tensor spectroscopy (DTS) and magne-
tization transfer ratio (MTR) – were reviewed as measures of
axonal diameter (DTS) and myelin volume (MTR). Combining
MTR with DTI, Palaniyappan et al. (61) recently showed that the
degree of FA reduction in areas with decreased myelin volume pre-
dicted impaired processing speed, leading the authors to suggest
that combined DTI/MTR could be used as a treatment measure in
the development of pro-cognitive drugs.
A study applying graph theory to analyze data from DTI com-
bined with MTR showed that patients with schizophrenia have a
weaker globally integrated structural brain network when com-
pared to healthy controls (62). The same study concluded that
the frontal hubs had a less central role than in healthy con-
trols, which is in accordance with a reduced structural capacity
to integrate information across brain regions. Moreover, a new
study combining DTI and resting-state fMRI comparing patients
with schizophrenia to healthy controls identified a selective dis-
ruption of brain connectivity among central hub regions with a
potential communication capacity reduction and brain dynamics
alterations (63).
MYELIN DEFICIENCIES IN SCHIZOPHRENIA
Compelling evidence from several different lines of research has,
in recent years, implicated dysfunctional myelin and oligoden-
drocytes, the cells responsible for wrapping myelin around neu-
ronal axons in the brain, in the pathology of schizophrenia and
related psychoses (22, 64–66). Sources of evidence include genetics
and pharmacogenetic studies, post-mortem studies, and as briefly
reviewed in the previous subsections of brain imaging studies,
particularly DTI studies.
Normal myelination starts in the late part of fetal life and occurs
most rapidly during the first 2 years after birth, but continues to
adulthood in a region- and brain matter-specific manner (22, 65,
67). Initial myelination occurs subcortically, thus increasing the
conduction velocities across different brain regions while leav-
ing the intra-cortical portion of the axon unmyelinated during
childhood (65). Interestingly, maturation of white matter in the
prefrontal cortex and in fronto-temporal tracts occurs later, in
late adolescence and early adult life, coinciding in time with the
peak age of schizophrenia onset (1). Possibly, disturbances in the
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maturation of myelin around the end of the myelination stage
could be one of the events contributing to the peak debut inci-
dence of schizophrenia in this age group (66). The prefrontal
cortex is one of the regions most robustly implicated in schizophre-
nia pathology, and working memory performance, which engages
this region, has been found to be positively associated with the
level of white matter maturation (67). Later intra-cortical myeli-
nation occurs for the most part in adulthood and is associated
with the refinement of cognitive functions and brain plasticity
(65). Importantly, myelination is a dynamic process, and oligo-
dendrocyte progenitor cells continue to differentiate throughout
life (68). In schizophrenia, intra-cortical myelin deficits seems to
be more pronounced than subcortical deficits, which have been
found to be more strongly associated with the duration of illness.
Indeed, evidence suggests that myelin integrity is closely related to
both cognitive functioning and to the symptoms of a variety of
psychiatric and neurological disorders (22, 46).
Alterations particularly in dopaminergic transmission (69, 70),
and also in the glutamatergic system, (11, 71) have been robustly
implicated in the pathology of schizophrenia for several decades.
Glutamatergic N -methyl-d-aspartate (NMDA) receptor antago-
nists, such as phencyclidine (PCP) and ketamine, have the poten-
tial to induce not only positive symptoms of psychosis but also
negative symptoms and cognitive dysfunction resembling those
seen in schizophrenia (11, 71). This has given rise to the NMDA
receptor hypofunction hypothesis of schizophrenia (21, 72). The
hypothesis has been extensively investigated in animal models but
several limitations related to how well evidence from preclinical
studies translate into schizophrenia patients have been pointed to
(72). Seemingly, paradoxically another model of schizophrenia-
related cognitive dysfunction is that of glutamatergic hyperactivity
(73). The model is based on other observations of increased pre-
frontal glutamate release following NMDA receptor antagonism.
The apparent paradoxical glutamate findings might be explained
by different NMDA receptor properties related to the different
locations and/or sub-compositions of the different NMDA recep-
tors as elaborated by Zhou et al. (74). Interestingly, there are several
points of convergence between myelin deficits and neurotrans-
mitter alterations. Firstly, glutamate is excitotoxic when in excess,
and oligodendrocyte progenitor cells display great vulnerability for
glutamatergic excitotoxicity (68). Increased glutamate levels have
been found in some phases of schizophrenia (75–77). Secondly,
there is emerging evidence that dysfunctional myelin and oligo-
dendrocytes could increase striatal dopamine levels, see Ref. (22)
for details. One example could be that if glutamatergic projections
from the prefrontal cortex to brainstem areas suffer from myelin
damage, this might lead to lower excitatory input at inhibitory
brainstem GABAergic interneurons, resulting in less inhibition of
dopaminergic mesolimbic projections and consequently striatal
hyperdopaminergia as outlined by Schwartz et al. (78).
MYELIN AS DRUG TARGET FOR PRESENT ANTIPSYCHOTICS
Animal studies suggest that myelin-protecting and oligodendrocyte-
stimulating properties may be a therapeutically relevant mech-
anism of action for at least some SGAs (61, 79, 80). In a DTI
study of schizophrenia patients in exacerbation, Garver et al.
(81) found increased diffusibility consistent with decreased myelin
integrity during acute psychosis. After initial examination, patients
were treated with the SGAs risperidone or ziprasidone, or the
FGA haloperidol, with partial restoration of myelin integrity after
4 weeks in the subgroup that responded to treatment. Bartzokis
et al. found higher volumes of intra-cortical myelin in schizo-
phrenia patients treated with oral risperidone compared to those
treated with the FGA fluphenazine decanoate (82). In a recent
study by the same group, the long acting injection formulation
of risperidone was associated with increased intra-cortical myelin
volume compared to the oral formulation of the same compound
(64). Myelin primarily consists of lipids, particularly cholesterol,
which are mainly synthesized de novo in the brain. Interestingly,
several antipsychotic agents have been demonstrated to directly
induce lipogenesis through the sterol regulatory element bind-
ing protein (SREBP) system, and these lipogenic effects have been
suggested to contribute to myelin-stimulating effects of antipsy-
chotic agents (83–85). In this regard, it is highly interesting that
clozapine, with its superior clinical efficacy, is also among the
antipsychotics associated with the most pronounced metabolic
adverse effects; in fact, a correlation between clinical improvement
and increase in serum lipid levels has repeatedly been demon-
strated (86–88). Summing up, a small but consistent body of
evidence indicates that some current SGAs have positive effects
on myelin volume, with possible distinctions among drugs and
drug formulations.
OTHER POTENTIAL “MYELIN-ENHANCING” TREATMENT OPTIONS
In a clinical randomized controlled trial (RCT) by Amminger
et al. (89), a markedly decreased progression rate to psychosis was
found in at risk subjects receiving high-dose polyunsaturated fatty
acids (PUFAs). PUFAs are involved in the myelination process,
and peripheral PUFA levels have been found to be decreased in
schizophrenia (90, 91). A recent DTI study in early-phase psy-
chosis patients found an association between level of PUFAs in
peripheral erythrocytes and white matter integrity (90). Possibly,
PUFA distribution is altered in patients at risk for psychosis, with a
link between PUFA levels and white matter integrity. Free radicals
can damage membrane PUFAs, and disturbances in fatty acids
and membrane phospholipid identified in patients with schizo-
phrenia may be caused by increased oxidative stress according to
a review by Yao and Keshavan (92). The same authors point to
disruption of antioxidative systems related to schizophrenia, with
reduced amounts of non-enzymatic plasma antioxidant compo-
nents [e.g., albumin, bilirubin, uric acid, ascorbic acid (vitamin
C), α-tocopherol (vitamin E)], see also the recent clinical study by
Zhang et al. demonstrating a reduced plasma total antioxidant sta-
tus in a sample of schizophrenia patients (93). Interestingly, PUFAs
also have mild anti-inflammatory effects, see Section “Additional
Drugs with Anti-Inflammatory Action as Add-on Treatments for
Patients with Schizophrenia.”
INFLAMMATION AND IMMUNOLOGY IN SCHIZOPHRENIA
IMPLICATING INFLAMMATORY SYSTEMS IN SCHIZOPHRENIA
Several findings point to a link between inflammatory processes
and the pathophysiology of schizophrenia: (1) activated periph-
eral inflammatory system and neuroinflammation in patients
with schizophrenia (94, 95), (2) evidence from genetic studies of
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correlation between schizophrenia and genes encoding for differ-
ent components of the immune system (96–98), (3) post-mortem
studies demonstrating up-regulated immune genes in the pre-
frontal cortex of patients with schizophrenia (99), (4) findings that
the raised risk of schizophrenia seen after maternal infections acts
via immunological mechanism (23), and (5) psychotic symptoms
and cognitive dysfunction caused by immunological neurological
syndromes (100), e.g., the interesting line of pathophysiological
evidence based on findings in autoimmune synaptic encephalitis
(limbic encephalitis), where antibody formation against NMDA
receptors is associated with a wide range of psychiatric symptoms,
in some patients also with syndromes resembling schizophrenia
(100). Binding of NMDA antibodies has been found predomi-
nantly in the hippocampus (101). Also, in systemic autoimmune
disorders such as systemic lupus erythematosus (SLE), patients
can suffer from various psychiatric syndromes, but the patho-
physiology has yet to be characterized in detail (102). A recent
remarkable finding is that the levels of soluble receptors for the
pro-inflammatory cytokine tumor necrosis factor (TNF)-α cor-
relates with function in patients with schizophrenia compared to
healthy individuals (103), the same study also found increased
levels of TNF-α in the treatment resistant group compared to
treatment responders.
In the following sections, we highlight some of the main
findings related to inflammation/immunology and schizophrenia,
with the specific purpose of evaluating the status of immune-
modulating treatment with cognitive-enhancing effects.
CYTOKINES
In the context of inflammatory changes in schizophrenia, the
majority of findings stem from the innate system, but components
of the adaptive immunology system have also been implicated.
The macrophages of the innate system induce the release of acute-
phase proteins [e.g., C-reactive protein (CRP) from hepatocytes]
as well as producing and releasing cytokines (97), all markers of
inflammation (104). Cytokines are also produced by peripher-
ally activated endothelial cells and monocyte-derived dendritic
cells (97).
PERIPHERAL INFLAMMATORY FINDINGS IN SCHIZOPHRENIA
Multiple studies have shown low-grade disturbances in the periph-
eral inflammatory system in patients with schizophrenia, see
recent reviews (105–107). Pro-inflammatory changes include ele-
vated serum measures of pro-inflammatory cytokines [interleukin
(IL)-1β, IL-6, IL-8, TNF-α] and other pro-inflammatory factors
[prostaglandin E2 (PGE2), CRP] and elevated monocyte counts
and activated immune cells have been associated with schizophre-
nia (108). Interestingly, some cytokines [IL-12, IFN-γ, TNF-α,
soluble IL-2 receptor (sIL-2R)] may be trait markers for schiz-
ophrenia, while others are raised during phases of intensified
symptoms (IL-1β, IL-6, and TGF-β) (106, 108). Furthermore,
some anti-inflammatory substances are elevated in subgroups
of patients with schizophrenia [soluble IL-1 receptor antagonist
(sIL-1RA), soluble IL-2 receptor antagonist (sIL-2RA), soluble
TNF receptors (sTNFRs)1, sTNFR2 (109), IL-10 (a cytokine with
anti-inflammatory properties), and transforming growth factor
(TGF)-β] (105). A review (110) identified decreased levels of IL-2
in patients with schizophrenia. IL-2 serves important functions in
T-cell-mediated immunologic reactions. Although the findings of
disturbances in the peripheral inflammatory system are not with-
out inconsistencies, and the measurements of cytokines are sensi-
ble to a wide range of confounders (e.g., the influence of antipsy-
chotic medication and metabolic status), there is firm evidence for
a mixed picture of peripheral pro- and anti-inflammatory changes
in a large proportion of patients with schizophrenia.
CENTRAL INFLAMMATORY FINDINGS IN PATIENTS WITH
SCHIZOPHRENIA
Brain neuroinflammation, in contrast to inflammation in other
parts of the body, does not lead to leukocyte recruitment, but
is characterized by activated microglia, the mononuclear phago-
cytes of the brain (111). Microglia develop from primitive myeloid
progenitors, and have various roles in the developing human brain
including synaptic pruning, remodeling of axons, neuronal dif-
ferentiation, and programed cell death (112). PET studies using
(R)[11C]PK11195 (95, 113) have found microglial activation in
schizophrenia, in addition to post-mortem studies demonstrat-
ing increased density and activation of microglia, though some
of these studies have yielded conflicting evidence (112). Activated
microglia have increased levels of the translocator protein (TPSO)
located at the mitochondrial membrane, and the binding of TPSO
to the (R)[11C]PK11195 is utilized in PET studies as a mea-
sure of neuroinflammation, while other PET ligands for activated
microglia are under development (113). Free-water imaging (114)
is another mode of neuroinflammation imaging, and studies using
this novel method have indicated widespread brain inflammation
and early signs of neurodegeneration in first-episode patients with
schizophrenia (115).
Microglia, astrocytes, and the kynurenine pathway
Activated microglia have many important functions besides
phagocytosis, including cytokine production (IL-1β, IL-12, and
TNF-α) (94, 111), most importantly crosstalk with the serotonin
and glutamate neurotransmitter systems, involving the kynure-
nine pathway (116). Activated microglia also induce functional
changes in brain astrocytes, which release IL-6, IL-10, and TGF-β
(94). In the presence of pro-inflammatory cytokines, e.g., IFN-
γ and TNF-α, tryptophan catabolism to kynurenins in microglia
and astrocytes is induced, resulting in the production of quino-
linic acid (QUIN) in microglia and KYNA in astrocytes. QUIN
is an NMDA agonist and potentially excitotoxic, while KYNA is
an NMDA antagonist and also blocks the α7 nicotinic acetyl-
choline receptor (α7nAChR) (94, 116). Figure 1 summarizes
major points of the activated inflammatory responses in schiz-
ophrenia. The demonstration of elevated levels of KYNA in the
cerebrospinal fluid (CSF) of patients with schizophrenia by two
independent groups (117, 118) in 2001 boosted research in brain
inflammatory-related processes implicated in schizophrenia. Ele-
vation of KYNA in the CSF and prefrontal cortex in patients
with schizophrenia is now an established finding, and is prob-
ably a consequence of peripheral inflammation according to a
recent review by Schwarcz et al. (119). Elevated levels of KYNA are
associated with decreased cognitive performance in animal mod-
els, including altered pre-pulse inhibition of the auditory startle
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FIGURE 1 | Characteristics, sources, and neuronal consequences of
activated inflammatory responses in schizophrenia. Abnormal
expression of inflammatory genes in monocytes/macrophages (M/M)
results in peripheral low-grade inflammation (patients: solid orange and
green lines-healthy subjects: dashed lines). Stress and/or pathogen
exposure may lead to an over-activation of microglia (MG), which activates
astrocytes (AC) and the consequent release of cytokines (IL-6, IL-10, TGF-β)
that stimulate the production of kynurenic acid (KYNA). KYNA blocks
signaling at the NMDA receptor and the α7 nicotinic acetylcholine receptor
(α7nAChR). MGs releases cytokines (IL-1β, IL-12, TNF-α) that weaken the
biosynthesis of serotonin and promotes the production of quinolinic acid
(QUIN) and 3-hydroxykynurenine (3-OHKY), both neurotoxic substances.
Abnormal HPA axis function may further contribute to the development of
low-grade inflammation as the normal feed-back exerted by cortisol is not
working properly. Furthermore, prenatal immune priming by in utero
exposure to infection may provide a developmental source of long-term
immune abnormalities to schizophrenia. With permission from Meyer et al.
(84).
response, deficits of working memory, and attentional set-shifting
paradigms (120, 121), while reducing KYNA resulted in improved
cognitive performance in a wide range of tasks (121). Adding to
this, the kynurenic pathway also offers a possible explanation of
how stress induces psychotic symptoms and cognitive dysfunction
in schizophrenia by linking increased levels of glucocorticoids to
the production of kynurenine in liver, subsequently converted to
KYNA in the brain (121). The kynurenic pathway offers several
potential drug targets for the reduction of brain KYNA levels,
which could improve cognitive function in schizophrenia. Can-
didate pharmacological agents related to schizophrenia treatment
block, e.g., the enzyme kynurenine aminotransferase (KAT), which
transforms kynurenine into KYNA. Most KYNA-lowering drugs
still lack behavioral data (122), while cerebrolysin, a peptider-
gic drug manufactured from purified porcine brain preparations,
which lower brain tissue KYNA levels in vitro (123) also have
been found to improve cognition (124). Interestingly, in a double
blind RCT of patients with schizophrenia cerebrolysin (intra-
venous infusion) as add-on treatment to risperidone was found
to improve scores at the Wechsler Adult Intelligence Scale and
the Wechsler Memory Scale (124). Cerebrolysin is generally well-
tolerated (125) and has also demonstrated pro-cognitive effects
in patients with dementia (126, 127) and traumatic brain injury
(128). In another recent study, d-cycloserine (DSC), a partial ago-
nist at the glycine site of the NMDA receptor, was also found to
reduce the levels of KYNA in human post-mortem frontal cortex
homogenates by dose-dependently blocking KAT (129). DSC has
also been found to improve memory consolidation and to reduce
delusions in combination with cognitive behavioral therapy (130).
IL-1β, S100B, BDNF
In addition to elevated KYNA/QUIN, other aspects of an acti-
vated brain immune system can also have clinically important
effects in schizophrenia. The proinflammatory cytokine IL-1β
has been linked to glutamatergic excitotoxicity (131), and close
dynamic interactions between IL-1β and the NMDA receptor
was the recently demonstrated (132). Pro-inflammatory cytokines
(e.g., IL-1) are also candidate causal agents implicated in the cere-
bral myelin damages discussed above, see (133, 134). The protein
S100B, produced by astrocytes, is a marker of astrocyte activa-
tion. Serving as an example of the pleiotropic effects associated
with many inflammatory factors at low concentration, S100B has
beneficial effects, limiting microglia activation, stress-related neu-
ronal damage, and increase glutamate uptake by astrocytes, while
at higher concentration it has detrimental effects, including induc-
tion of microglial TNF-α secretion and induced production of, e.g.,
COX2/PGE-2, IL-1β, etc. (135). A meta-analysis concluded that
serum levels of S100B may be elevated in schizophrenia, and dis-
ruptions of the blood–brain barrier (BBB) and/or active secretion
by astrocytes were suggested as possible causes (136).
The neurotrophin BDNF is among the substances secreted by
immune cells during inflammation and immune responses (137),
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and an inverse relationship between levels of BDNF and certain
cytokines has been found (138). BDNF has been implicated in
widespread processes relevant to the pathophysiology of schiz-
ophrenia including neurodevelopment, synapse regulation, and
neuroplasticity, as well as effects on cognition, see for example
(138–140). BDNF has been found to be reduced in schizophrenia
in both drug-naïve and chronic patients, although findings are not
entirely consistent across studies. Furthermore, an association has
been found between reduced neurocognitive function and reduced
serum BDNF levels (139). BDNF interacts with dopaminergic,
glutamatergic, and serotonergic systems in the brain, see Nurjono
et al. (138) for a recent update. Regarding BDNF as a drug target,
FGAs have been reported to lower peripheral BDNF, whereas SGAs
either have no effect or increase BDNF, while antidepressants have
been shown to increase BDNF (140).
STRUCTURAL AND FUNCTIONAL CORRELATES OF INFLAMMATORY
DISTURBANCES IN PATIENTS WITH SCHIZOPHRENIA
Structural brain alterations associated with immune-related
genetic polymorphisms were recently reviewed by Fineberg and
Ellman (107). The review identified associations between variabil-
ity in the IL-1 gene complex and white and gray matter volume
reductions in temporal and frontal brain regions, together with
enlarged ventricles in patients with schizophrenia. Furthermore,
this review discussed associations of IL-1 gene variations with
decreased dorsolateral prefrontal function during different neu-
rocognitive tasks (107). In another review, Meyer (105) found
evidence for a positive correlation between the severity of cog-
nitive deficits and the peripheral levels of IL-1β, IL-6, TNF-α,
CRP, and S100B. While the correlation of the inflammatory dis-
turbances with specific cognitive effects is not clarified in patients
with schizophrenia, findings from animal studies and studies in
non-schizophrenic individuals reveal associations of inflamma-
tory disturbances with executive function, sustained attention, and
working memory according to the review by Meyer et al. (105).
ANTI-INFLAMMATORY EFFECTS OF ANTIPSYCHOTIC DRUGS
Monji et al. (141) recently reviewed studies (mostly in vitro and
animal studies) concerning the capability of antipsychotic drugs to
influence activated microglia. The review identified several studies
showing that antipsychotic drugs significantly reduce the secretion
of TNF-α, nitric oxide, IL-1β, and IL-2 from activated microglia.
Furthermore, some drugs were found to have stronger inhibitory
effects, e.g., risperidone, which inhibited the secretion of several
cytokines from activated microglia more than haloperidol, and
indications of clozapine-specific effects have also been reported.
Moreover, in the context of the kynurenine pathway, one ani-
mal study demonstrated that chronic treatment with antipsychotic
drugs reduces brain KYNA (142). Meyer et al. (94) reviewed the
influence of antipsychotic treatment on peripheral cytokines in
clinical populations and found that antipsychotics reduced the
level of proinflammatory cytokines (IL-1β, IL-6, sIL-6R, TNF-α)
while increasing peripheral production of anti-inflammatory sub-
stances such as (sIL-1RA, sIL-2R and IL-10). Here, SGAs seemed to
have the most pronounced effects and a possible relation between
the ability to normalize immune function and clinical effects were
identified. Brain imaging studies investigating antipsychotic drug
treatment in brain imaging paradigms capable of showing effects
on neuroinflammation (e.g., PET/“free water” MRI) would truly
improve this field of research, but we have not been able to identify
any such studies.
THE EFFECTS OF ANTI-INFLAMMATORY/IMMUNE-MODULATING
DRUGS IN THE TREATMENT OF SCHIZOPHRENIA
Non-steroid anti-inflammatory drugs
Based on the notion of activated immune responses in the brain
and/or peripheral tissues, a few clinical studies have evaluated the
effects of non-steroid anti-inflammatory drugs (NSAIDs) in schiz-
ophrenia. The pooled effects size in reducing total Positive and
Negative Syndrome Scale (PANSS) score according to a recent
meta-analysis of the effect of add-on treatment with NSAIDs
[eight studies, two with aspirin (n= 270), six with celecoxib
(n= 504)] to different antipsychotics showed non-significant ben-
efit over placebo (143). Treatment with aspirin alone was superior
to placebo, while treatment with celecoxib was not; these conclu-
sions were also drawn in a meta-analysis of Sommer et al. (144).
When the studies were categorized according to disease phase,
the pooled analyses of all eight studies revealed positive effects of
NSAIDs vs. placebo for first-episode patients. The authors con-
cluded that the present data do not lend significant support to
NSAIDs as add-on therapy to antipsychotic treatment for patients
with schizophrenia. Another review agreed that indiscriminately
suppressing inflammation seems not to be the optimal way of
treating immunological disturbances associated with schizophre-
nia, and that treatment should aim at reversing glial loss, upreg-
ulating beneficial microglial activation and proliferation (MAP)
together with other neuroprotective measures, while ideally down-
regulating harmful aspects of MAP (135). At present, studies more
precisely aiming to elucidate the putative pro-cognitive effects of
treatment with NSAIDs in patients with schizophrenia are lack-
ing, although non-significant effects were demonstrated in a small
study (145).
Erythropoietin
Erythropoietin (EPO) is a cytokine with several identified func-
tions in the brain (146). In a 12-week, placebo-controlled study
(n= 39) with stable schizophrenia patients, treatment with recom-
binant human EPO (40000 IU/week) improved neurocognitive
function compared to placebo in the domains of delayed mem-
ory, language-semantic fluency, attention and perseverative errors
(147). An evaluation of gray matter development in the same study
showed that gray matter loss was significantly less pronounced
in the group treated with EPO (148). Animal studies have sup-
ported a pro-cognitive effect of EPO treatment (146). A systematic
review identified multiple putative beneficial brain targets of EPO
treatment, e.g., modulation of inflammation, neuroprotection,
neurotransmission regulation, effects on BBB permeability, but
the use of EPO can be limited by adverse effects such as thrombo-
sis and cancer (149). EPO has also been found to improve cognitive
function in studies of patients with Parkinson’s disease (150) and
multiple sclerosis (151).
Minocycline
The tetracycline antibiotic drug minocycline has also been tested
as an add-on treatment for patients with schizophrenia, based on
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evidence from animal studies that showed minocycline to have
multiple actions including inhibition of microglial activation and
the attenuation of adaptive immunity through the reduction of
activity and expression of matrix metalloproteinases (MMPs).
MMPs enable T-cells to migrate through the BBB by altering its
permeability, a process associated with myelin degradation (152).
In a placebo-controlled, 6-month trial in patients with schizophre-
nia (54 patients receiving 200 mg minocycline and 26 patients
receiving placebo), cognitive function (and negative symptoms)
improved significantly in the minocycline-treated group, partic-
ularly in the domains of working memory, cognitive flexibility,
and planning (153). Chaudry et al. (154) reported the results of
a 1-year RCT of 155 early schizophrenia patients performed in
Brazil and Pakistan, where minocycline reduced negative symp-
toms (adjusted difference 95% confidence interval 1.55–5.51 at
the PANSS negative subscale), but no significant effects of treat-
ment were found in tests for cognitive function. The meta-analysis
of Sommer et al. (144) identified four RCT studies with n= 182
patients given minocycline, and n= 166 on placebo, the effects on
cognition were not reported, but no significant effects on overall
symptom severity were identified.
Additional drugs with anti-inflammatory action as add-on
treatments for patients with schizophrenia
The meta-analysis by Sommer et al. (144) also investigated the
effect of additional anti-inflammatory treatments. The outcome
measure was the mean change in PANSS (155) or the Brief
Psychiatric Rating Scale (156), and significant improvements of
treatment with n-acetylcysteine (n= 140), aspirin (n= 270), and
estrogens (n= 262) were identified, while studies with davunetide
and PUFAs (eicosapentanoic acid and docosahexanoic acids) did
not show significant effects.
SUMMING UP PRO-COGNITIVE EFFECTS OF
IMMUNOMODULATING/ANTI-INFLAMMATORY DRUG TREATMENT FOR
PATIENTS WITH SCHIZOPHRENIA: CRITICAL METHODOLOGICAL
PROBLEMS REMAIN
The involvement of inflammatory/immunological factors in the
pathophysiology of a large portion of patients with schizophre-
nia is well established through different lines of research, and
data point to several links between these factors and cogni-
tive dysfunction. Presently, many drugs with anti-inflammatory
or immunomodulatory action have been tested (as add-on to
antipsychotic treatment) for patients with schizophrenia, and
while some have shown positive effects for global schizophrenia
symptoms, the effects on cognition were not possible to assess in
the recent meta-analysis by Sommer et al. (144), as only 5 of 26
included studies reported data on cognitive tests and the hetero-
geneity of the cognitive tasks made it impossible to quantitatively
review the effects. Furthermore, as highlighted by Sommer et al.
the drugs tested that were shown to improve the symptoms of
schizophrenia (N -acetylcysteine, estrogens, aspirin) have broad
mechanisms of action, and it is not at all demonstrated that the
improved symptoms are caused by anti-inflammatory actions.
A further critical question to address in future drug research will
be to establish reliable brain imaging methods to quantitatively
assess neuroinflammation, as the levels of peripheral cytokines are
only an indirect measure of brain neuroinflammation. PET stud-
ies with new ligands that specifically target activated microglia
and the “free-water” MRI scanning seem promising, but extensive
development remains before these methods are ready as outcome
measures in drug discovery studies.
SUMMARY AND CONVERGENCE
At present, pharmacological treatment of schizophrenia relies on
antipsychotic drugs, which predominantly relieve positive psy-
chotic symptoms and have little effect on the cognitive dys-
functions restricting the functional level of patients. However,
recent developments in brain imaging, including novel specific
PET ligands and MRI paradigms specifically investigating myelin
integrity, neurotransmitter levels, and neuroinflammation, facili-
tate the unraveling of mechanisms underlying cognitive dysfunc-
tion in schizophrenia. Accumulating evidence supports a com-
bined model including all these areas of pathology underlying
the cognitive deficits in schizophrenia, schematically exemplified
by Figure 2 for the interplay between prefrontal cortex, striatum,
and brain stem. This joint model represents several potential pro-
cognitive drug targets at the level of neurotransmitters, lipids,
and inflammatory markers, however, no current drugs aimed at
these targets are so far definitely proven to be clinically useful as
pro-cognitive drugs for patients with schizophrenia. Studies con-
cerning immunomodulatory drugs, including EPO, minocycline,
celecoxib, aspirin, estrogens, n-acetylcysteine have shown promis-
ing results in single studies, but have not yielded straightforward
support for the use in clinical practice to enhance cognition.
FUTURE PERSPECTIVES
Drugs that would reduce brain levels of KYNA (e.g., KAT
inhibitors) are expected to improve cognitive dysfunctions in
schizophrenia based on animal studies, but remain to be devel-
oped for clinical use. The possibility of pro-cognitive effects of
drugs that have been used to treat other medical conditions for
years, e.g., EPO, minocycline, and aspirin is attractive, also because
the safety profile of many of these drugs are well known in neu-
rological patients populations, reducing the costs of introducing
the drugs as cognitive enhancers for schizophrenia patients. Sev-
eral critical questions currently constraining progress remain to
be solved, however. Firstly, uniformly accepted and standardized
cognitive assessments for repeated measures must be agreed on
for pro-cognitive drug studies in schizophrenia patients. Secondly,
the refinement of brain imaging methods unto sufficient reliabil-
ity and specificity (e.g., measuring neuroinflammation and myelin
integrity) for use as outcome measures in pro-cognitive drug is
essential for studies of putative cognition enhancers in humans.
Thirdly, and at least of prominent importance in the field of further
developments of pro-cognitive glutamatergic substances are the
problems of translating findings in animal studies to human drug
treatment.
However, even though the process of developing novel phar-
macological agents is highly sophisticated, identifying novel treat-
ment targets through thorough clinical and preclinical studies
remains pivotal in the continued search for improved treatment
of schizophrenia. The convergence of a disordered inflammatory
system, disturbances in myelination/oligodendrocyte function,
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FIGURE 2 | Simplified putative interplay between selected
neurotransmitters, oligodendrocytes, and inflammation in the
pathology of cognitive dysfunctions in schizophrenia. Green
cell=excitatory pyramidal glutamatergic (GLU) neuron; red cell= inhibitory
GABAergic (GABA) interneuron; blue cell=modulatory dopaminergic (D)
neuron; light blue cell=oligodendrocyte (O) with white myelin sheets
enclosing the pyramidal cell axon; KYNA= kynurenic acid,
QUIN=quinolinic acid. The figure displays some putative points of
convergence between neurotransmitters, myelin, and neuroinflammation
relevant to the cognitive dysfunctions of schizophrenia. Details are
elaborated in the text. (1) In the prefrontal cortex, abnormal NMDA
functioning on, and/or deficient GABA release and reuptake in a subset of
GABAergic interneurons result in deficient negative feedback on pyramidal
glutamatergic neurons, which may lead to glutamatergic hyperactivity,
excitotoxicity, and disruption of coordinated firing of pyramidal cells. (2)
Deficient glutamatergic neuronal activity leads to decreased excitatory
input on GABAergic interneurons terminating on dopaminergic projections
to striatum, leading to striatal hyperdopaminergia. The hyperdopaminergia
may inversely influence cognitive functions located in the prefrontal
cortex. (3) Reduced myelin integrity may inversely influence glutamatergic
signaling leading to the same consequences as in the point above.
Oligodendrocytes express NMDA receptors and are thus vulnerable for
excitotoxicity from excess glutamate and QUIN. (4) During inflammation
QUIN is produced in microglia and KYNA in astrocytes. QUIN is an NMDA
agonist and potentially excitotoxic, while KYNA is an NMDA antagonist
that could induce cognitive dysfunctions consistent with the NMDA
receptor hypofunction hypothesis of schizophrenia. Adapted with
permission from Lisman et al. (72) and Takahashi et al. (102).
and transmitter dysfunctions in schizophrenia open new paths
for pro-cognitive drug discovery with putative large functional
improvements to be achieved for patients with schizophrenia.
ACKNOWLEDGMENTS
Parts of the research were funded by grants to Erik Johnsen from
the Research Council of Norway, project no. 213727, and sev-
eral grants from Helse Vest. Parts of the research were funded
by an ERC Advanced Grant and by the NORMENT SFF from
the Research Council of Norway to Kenneth Hugdahl and Silje
Skrede.
REFERENCES
1. Tandon R, Nasrallah HA, Keshavan MS. Schizophrenia, “just the facts”
4. Clinical features and conceptualization. Schizophr Res (2009) 110:1–23.
doi:10.1016/j.schres.2009.03.005
2. World Health Organization. The World Health Report 2001 – Mental Health:
New Understanding, New Hope. Geneva: WHO (2001).
3. Ustun TB, Rehm J, Chatterji S, Saxena S, Trotter R, Room R, et al. Multiple-
informant ranking of the disabling effects of different health conditions in
14 countries. WHO/NIH Joint Project CAR Study Group. Lancet (1999)
354:111–5. doi:10.1016/S0140-6736(98)07507-2
4. Tandon R. Antipsychotics in the treatment of schizophrenia: an overview. J Clin
Psychiatry (2011) 72(Suppl 1):4–8. doi:10.4088/JCP.10075su1.01
5. Miyamoto S, Miyake N, Jarskog LF, Fleischhacker WW, Lieberman JA. Phar-
macological treatment of schizophrenia: a critical review of the pharmacology
and clinical effects of current and future therapeutic agents. Mol Psychiatry
(2012) 17(12):1206–27. doi:10.1038/mp.2012.47
6. Shen WW. A history of antipsychotic drug development. Compr Psychiatry
(1999) 40:407–14. doi:10.1016/S0010-440X(99)90082-2
7. Leucht S, Cipriani A, Spineli L, Mavridis D, Orey D, Richter F, et al. Com-
parative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a
multiple-treatments meta-analysis. Lancet (2013) 382(9896):951. doi:10.1016/
S0140-6736(13)60733-3
8. Meltzer HY. Update on typical and atypical antipsychotic drugs. Annu Rev Med
(2012) 64:393–406. doi:10.1146/annurev-med-050911-161504
9. Meltzer HY, Massey BW. The role of serotonin receptors in the action of atypi-
cal antipsychotic drugs. Curr Opin Pharmacol (2011) 11:59–67. doi:10.1016/j.
coph.2011.02.007
www.frontiersin.org February 2014 | Volume 5 | Article 11 | 9
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Kroken et al. A critical review of pro-cognitive drug targets
10. Meltzer HY, Matsubara S, Lee JC. Classification of typical and atypical antipsy-
chotic drugs on the basis of dopamine D-1, D-2 and serotonin2 pKi values.
J Pharmacol Exp Ther (1989) 251:238–46.
11. Kantrowitz JT, Javitt DC. N-methyl-d-aspartate (NMDA) receptor dysfunction
or dysregulation: the final common pathway on the road to schizophrenia?
Brain Res Bull (2010) 83:108–21. doi:10.1016/j.brainresbull.2010.04.006
12. Gray JA, Roth BL. The pipeline and future of drug development in schizophre-
nia. Mol Psychiatry (2007) 12:904–22. doi:10.1038/sj.mp.4002062
13. Gray JA, Roth BL. Molecular targets for treating cognitive dysfunction in schiz-
ophrenia. Schizophr Bull (2007) 33:1100–19. doi:10.1093/schbul/sbm074
14. Demjaha A, Egerton A, Murray RM, Kapur S, Howes OD, Stone JM, et al.
Antipsychotic treatment resistance in schizophrenia associated with elevated
glutamate levels but normal dopamine function. Biol Psychiatry (2013).
doi:10.1016/j.biopsych.2013.06.011
15. Green MF. What are the functional consequences of neurocognitive deficits in
schizophrenia? Am J Psychiatry (1996) 153:321–30.
16. Palmer BW, Dawes SE, Heaton RK. What do we know about neuropsy-
chological aspects of schizophrenia? Neuropsychol Rev (2009) 19:365–84.
doi:10.1007/s11065-009-9109-y
17. Chou H-H, Twamley E, Swerdlow N. Towards medication-enhancement of
cognitive interventions in schizophrenia. In: Geyer MA, Gross G, editors. Novel
Antischizophrenia Treatments. Berlin: Springer (2012). p. 81–111.
18. Lameh J, McFarland K, Ohlsson J, Ek F, Piu F, Burstein E, et al. Discovery
of potential antipsychotic agents possessing pro-cognitive properties. Naunyn
Schmiedebergs Arch Pharmacol (2012) 385:313–23. doi:10.1007/s00210-011-
0702-2
19. Insel TR,Voon V, Nye JS, Brown VJ, Altevogt BM, Bullmore ET, et al. Innovative
solutions to novel drug development in mental health. Neurosci Biobehav Rev
(2013) 37(10 Pt 1):2438–44. doi:10.1016/j.neubiorev.2013.03.022
20. Williams M. Productivity shortfalls in drug discovery: contributions from the
preclinical sciences? J Pharmacol Exp Ther (2011) 336:3–8. doi:10.1124/jpet.
110.171751
21. Marek GJ, Behl B, Bespalov AY, Gross G, Lee Y, Schoemaker H. Glutamater-
gic (N-methyl-d-aspartate receptor) hypofrontality in schizophrenia: too little
juice or a miswired brain? Mol Pharmacol (2010) 77:317–26. doi:10.1124/mol.
109.059865
22. Takahashi N, Sakurai T, Davis KL, Buxbaum JD. Linking oligodendrocyte and
myelin dysfunction to neurocircuitry abnormalities in schizophrenia. Prog
Neurobiol (2011) 93:13–24. doi:10.1016/j.pneurobio.2010.09.004
23. Anderson G, Berk M, Dodd S, Bechter K, Altamura AC, Dell’Osso B, et al.
Immuno-inflammatory, oxidative and nitrosative stress, and neuroprogres-
sive pathways in the etiology, course and treatment of schizophrenia. Prog
Neuropsychopharmacol Biol Psychiatry (2013) 42:1–4. doi:10.1016/j.pnpbp.
2012.07.016
24. Millan MJ, Agid Y, Brüne M, Bullmore ET, Carter CS, Clayton NS, et al.
Cognitive dysfunction in psychiatric disorders: characteristics, causes and
the quest for improved therapy. Nat Rev Drug Discov (2012) 11:141–68.
doi:10.1038/nrd3628
25. Kahn RS, Keefe RE. Schizophrenia is a cognitive illness: time for a change in
focus. JAMA Psychiatry (2013) 70(10):1107–12. doi:10.1001/jamapsychiatry.
2013.155
26. Weinberger DR. From neuropathology to neurodevelopment. Lancet (1995)
346:552–7. doi:10.1016/S0140-6736(95)91386-6
27. Caspi A, Reichenberg A, Weiser M, Rabinowitz J, Kaplan Z, Knobler H, et al.
Cognitive performance in schizophrenia patients assessed before and following
the first psychotic episode. Schizophr Res (2003) 65:87–94. doi:10.1016/S0920-
9964(03)00056-2
28. Gschwandtner U, Aston J, Borgwardt S, Drewe M, Feinendegen C, Lacher
D, et al. Neuropsychological and neurophysiological findings in individuals
suspected to be at risk for schizophrenia: preliminary results from the Basel
early detection of psychosis study – Fruherkennung von Psychosen (FEPSY).
Acta Psychiatr Scand (2003) 108:152–5. doi:10.1034/j.1600-0447.2003.00157.x
29. Heaton RK, Gladsjo J, Palmer BW, Kuck J, Marcotte TD, Jeste DV. Stability and
course of neuropsychological deficits in schizophrenia. Arch Gen Psychiatry
(2001) 58:24–32. doi:10.1001/archpsyc.58.1.24
30. Rund BR. A review of longitudinal studies of cognitive functions in schizo-
phrenia patients. Schizophr Bull (1998) 24:425–35. doi:10.1093/oxfordjournals.
schbul.a033337
31. Nuechterlein KH, Barch DM, Gold JM, Goldberg TE, Green MF, Heaton RK.
Identification of separable cognitive factors in schizophrenia. Schizophr Res
(2004) 72:29–39. doi:10.1016/j.schres.2004.09.007
32. Dickinson D, Ramsey ME, Gold JM. Overlooking the obvious: a meta-analytic
comparison of digit symbol coding tasks and other cognitive measures in
schizophrenia. Arch Gen Psychiatry (2007) 64:532–42. doi:10.1001/archpsyc.
64.5.532
33. Heinrichs R, Zakzanis K. Neurocognitive deficit in schizophrenia: a quantita-
tive review of the evidence. Neuropsychology (1998) 12:426–45. doi:10.1037/
0894-4105.12.3.426
34. Wilk CM, Gold JM, Bartko JJ, Dickerson F, Fenton WS, Knable M, et al.
Test-retest stability of the repeatable battery for the assessment of neu-
ropsychological status in schizophrenia. Am J Psychiatry (2002) 159:838–44.
doi:10.1176/appi.ajp.159.5.838
35. Wilk CM, Gold JM, Humber K, Dickerson F, Fenton WS, Buchanan RW. Brief
cognitive assessment in schizophrenia: normative data for the repeatable bat-
tery for the assessment of neuropsychological status. Schizophr Res (2004)
70:175–86. doi:10.1016/j.schres.2003.10.009
36. Gold MJ, Queern C, Iannone VN, Buchanan RW. Repeatable battery for the
assessment of neuropsychological status as a screening test in schizophrenia I:
sensitivity, reliability, and validity. Am J Psychiatry (1999) 156:1944–50.
37. Keefe RS. Should cognitive impairment be included in the diagnostic criteria
for schizophrenia? World Psychiatry (2008) 7:22–8. doi:10.1002/j.2051-5545.
2008.tb00142.x
38. Green MF, Kern RS, Braff DL, Mintz J. Neurocognitive deficits and functional
outcome in schizophrenia: are we measuring the “right stuff”? Schizophr Bull
(2000) 26:119–36. doi:10.1093/oxfordjournals.schbul.a033430
39. Kaneda Y, Jayathilak K, Meltzer HY. Determinants of work outcome in schizo-
phrenia and schizoaffective disorder: role of cognitive function. Psychiatry Res
(2009) 169:178–9. doi:10.1016/j.psychres.2008.08.003
40. Laes JR, Sponheim SR. Does cognition predict community function only in
schizophrenia? A study of schizophrenia patients, bipolar affective disorder
patients, and community control subjects. Schizophr Res (2006) 84:121–31.
doi:10.1016/j.schres.2005.11.023
41. Tsang HW, Leung AY, Chung RC, Bell M, Cheung WM. Review on vocational
predictors: a systematic review of predictors of vocational outcomes among
individuals with schizophrenia: an update since 1998. Aust N Z J Psychiatry
(2010) 44:495–504. doi:10.3109/00048671003785716
42. McClure MM, Bowie CR, Patterson TL, Heaton RK, Weaver C, Anderson H,
et al. Correlations of functional capacity and neuropsychological performance
in older patients with schizophrenia: evidence for specificity of relationships?
Schizophr Res (2007) 89:330–8. doi:10.1016/j.schres.2006.07.024
43. Nuechterlein K, Green M, Kern R, Baade L, Barch D, Cohen J, et al.
The MATRICS consensus cognitive battery, part 1: test selection, reliability,
and validity. Am J Psychiatry (2008) 165:203–13. doi:10.1176/appi.ajp.2007.
07010042
44. Keefe RS, Fox KH, Harvey PD, Cucchiaro J, Siu C, Loebel A. Characteristics
of the MATRICS consensus cognitive battery in a 29-site antipsychotic schiz-
ophrenia clinical trial. Schizophr Res (2011) 125:161–8. doi:10.1016/j.schres.
2010.09.015
45. Burton CZ, Vella L, Harvey PD, Patterson TL, Heaton RK, Twamley EW. Factor
structure of the MATRICS consensus cognitive battery (MCCB) in schizophre-
nia. Schizophr Res (2013) 146:244–8. doi:10.1016/j.schres.2013.02.026
46. Fields RD. White matter in learning, cognition and psychiatric disorders. Trends
Neurosci (2008) 31:361–70. doi:10.1016/j.tins.2008.04.001
47. Puri BK. Progressive structural brain changes in schizophrenia. Expert Rev
Neurother (2010) 10:33–42. doi:10.1586/ern.09.142
48. Ellison-Wright I, Bullmore E. Meta-analysis of diffusion tensor imaging
studies in schizophrenia. Schizophr Res (2009) 108:3–10. doi:10.1016/j.schres.
2008.11.021
49. Walterfang M, Wood SJ, Velakoulis D, Pantelis C. Neuropathological,
neurogenetic and neuroimaging evidence for white matter pathology in schiz-
ophrenia. Neurosci Biobehav Rev (2006) 30:918–48. doi:10.1016/j.neubiorev.
2006.02.001
50. Rigucci S, Rossi-Espagnet C, Ferracuti S, De Carolis A, Corigliano V, Carducci
F, et al. Comparelli, anatomical substrates of cognitive and clinical dimen-
sions in first episode schizophrenia. Acta Psychiatr Scand (2012) 128:261–70.
doi:10.1111/acps.12051
Frontiers in Psychiatry | Schizophrenia February 2014 | Volume 5 | Article 11 | 10
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Kroken et al. A critical review of pro-cognitive drug targets
51. Nazeri A, Mallar Chakravarty M, Felsky D, Lobaugh NJ, Rajji TK, Mulsant
BH, et al. Alterations of superficial white matter in schizophrenia and relation-
ship to cognitive performance. Neuropsychopharmacology (2013) 38:1954–62.
doi:10.1038/npp.2013.93
52. Ruiz S, Birbaumer N, Sitaram R. Abnormal neural connectivity in schizophre-
nia and fMRI-brain-computer interface as a potential therapeutic approach.
Front Psychiatry (2013) 4:17. doi:10.3389/fpsyt.2013.00017
53. Fornito A, Zalesky A, Pantelis C, Bullmore ET. Schizophrenia, neuroimag-
ing and connectomics. Neuroimage (2012) 62:2296–314. doi:10.1016/j.
neuroimage.2011.12.090
54. Pettersson-Yeo W, Allen P, Benetti S, McGuire P, Mechelli A. Dysconnectivity in
schizophrenia: where are we now? Neurosci Biobehav Rev (2011) 35:1110–24.
doi:10.1016/j.neubiorev.2010.11.004
55. Hugdahl K, Loberg EM, Nygard M. Left temporal lobe structural and func-
tional abnormality underlying auditory hallucinations in schizophrenia. Front
Neurosci (2009) 3:34–45. doi:10.3389/neuro.01.001.2009
56. Raichle M. Two views of brain function. Trends Cogn Sci (2010) 14:180–90.
doi:10.1016/j.tics.2010.01.008
57. Hugdahl K, Løberg E-M, Nygård M. Left temporal lobe structural and func-
tional abnormality underlying auditory hallucinations. Front Neurosci (2009)
3(1):34–45. doi:10.3389/neuro.01.001.2009
58. Hugdahl K, Rund B, Lund A, Asbjørnsen A, Egeland J, Landrø N, et al.
Brain activation measured with fMRI during a mental arithmetic task in
schizophrenia and major depression. Am J Psychiatry (2004) 161(2):286–93.
doi:10.1176/appi.ajp.161.2.286
59. Alexander A, Lee J, Lazar M, Field A. Diffusion tensor imaging of the brain.
Neurotherapeutics (2007) 4:316–29. doi:10.1016/j.nurt.2007.05.011
60. Ongur D, Du F. Probing myelin and axon abnormalities separately in psy-
chiatric disorders using MRI techniques. Front Integr Neurosci (2013) 7:24.
doi:10.3389/fnint.2013.00024
61. Kimoto S, Okuda A, Toritsuka M, Yamauchi T, Makinodan M, Okuda H, et al.
Olanzapine stimulates proliferation but inhibits differentiation in rat oligo-
dendrocyte precursor cell cultures. Prog Neuropsychopharmacol Biol Psychiatry
(2011) 35:1950–6. doi:10.1016/j.pnpbp.2011.07.011
62. van den Heuvel MP, Mandl RC, Stam CJ, Kahn RS, Hulshoff Pol HE. Aberrant
frontal and temporal complex network structure in schizophrenia: a graph
theoretical analysis. J Neurosci (2010) 30:15915–26. doi:10.1523/JNEUROSCI.
2874-10.2010
63. van den Heuvel MP, Sporns O, Collin G, Scheewe T, Mandl RC, Cahn W, et al.
Abnormal rich club organization and functional brain dynamics in schizo-
phrenia. JAMA Psychiatry (2013) 70:783–92. doi:10.1001/jamapsychiatry.2013.
1328
64. Bartzokis G, Lu PH, Raven EP, Amar CP, Detore NR, Couvrette AJ, et al. Impact
on intracortical myelination trajectory of long acting injection versus oral
risperidone in first-episode schizophrenia. Schizophr Res (2012) 140:122–8.
doi:10.1016/j.schres.2012.06.036
65. Bartzokis G. Neuroglialpharmacology: myelination as a shared mechanism
of action of psychotropic treatments. Neuropharmacology (2012) 62:2137–53.
doi:10.1016/j.neuropharm.2012.01.015
66. Catts VS, Fung SJ, Long LE, Joshi D, Vercammen A, Allen KM, et al. Rethinking
schizophrenia in the context of normal neurodevelopment. Front Cell Neurosci
(2013) 7:60. doi:10.3389/fncel.2013.00060
67. Fields RC, Aft RL, Gillanders WE, Eberlein TJ, Margenthaler JA. Treatment
and outcomes of patients with primary breast sarcoma. Am J Surg (2008)
196:559–61. doi:10.1016/j.amjsurg.2008.06.010
68. Walterfang M, Velakoulis D, Whitford TJ, Pantelis C. Understanding aberrant
white matter development in schizophrenia: an avenue for therapy? Expert Rev
Neurother (2011) 11:971–87. doi:10.1586/ern.11.76
69. Howes OD, Kapur S. The dopamine hypothesis of schizophrenia: version III –
the final common pathway. Schizophr Bull (2009) 35:549–62. doi:10.1093/
schbul/sbp006
70. Howes OD, Kambeitz J, Kim E, Stahl D, Slifstein M, Abi-Dargham A,
et al. The nature of dopamine dysfunction in schizophrenia and what this
means for treatment. Arch Gen Psychiatry (2012) 69:776–86. doi:10.1001/
archgenpsychiatry.2012.169
71. Snyder MA, Gao WJ. NMDA hypofunction as a convergence point for pro-
gression and symptoms of schizophrenia. Front Cell Neurosci (2013) 7:31.
doi:10.3389/fncel.2013.00031
72. Gilmour G, Dix S, Fellini L, Gastambide F, Plath N, Steckler T, et al. NMDA
receptors, cognition and schizophrenia – testing the validity of the NMDA
receptor hypofunction hypothesis. Neuropharmacology (2012) 62:1401–12.
doi:10.1016/j.neuropharm.2011.03.015
73. Javitt DC. Glutamate as a therapeutic target in psychiatric disorders. Mol Psy-
chiatry (2004) 9:984–97, 979. doi:10.1038/sj.mp.4001602
74. Zhou Q, Sheng M. NMDA receptors in nervous system diseases. Neurophar-
macology (2013) 74:69–75. doi:10.1016/j.neuropharm.2013.03.030
75. Theberge J, Bartha R, Drost DJ, Menon RS, Malla A, Takhar J, et al. Gluta-
mate and glutamine measured with 4.0 T proton MRS in never-treated patients
with schizophrenia and healthy volunteers. Am J Psychiatry (2002) 159:1944–6.
doi:10.1176/appi.ajp.159.11.1944
76. Olbrich HM, Valerius G, Rusch N, Buchert M, Thiel T, Hennig J, et al. Fron-
tolimbic glutamate alterations in first episode schizophrenia: evidence from a
magnetic resonance spectroscopy study. World J Biol Psychiatry (2008) 9:59–63.
doi:10.1080/15622970701227811
77. Ota M, Ishikawa M, Sato N, Hori H, Sasayama D, Hattori K, et al. Glutamater-
gic changes in the cerebral white matter associated with schizophrenic exacer-
bation. Acta Psychiatr Scand (2012) 126:72–8. doi:10.1111/j.1600-0447.2012.
01853.x
78. Schwartz TL, Sachdeva S, Stahl SM. Glutamate neurocircuitry: theoretical
underpinnings in schizophrenia. Front Pharmacol (2012) 3:195. doi:10.3389/
fphar.2012.00195
79. Xiao L, Xu H, Zhang Y, Wei Z, He J, Jiang W, et al. Quetiapine facilitates
oligodendrocyte development and prevents mice from myelin breakdown
and behavioral changes. Mol Psychiatry (2008) 13:697–708. doi:10.1038/sj.mp.
4002064
80. Zhang Y, Xu H, Jiang W, Xiao L, Yan B, He J, et al. Quetiapine alle-
viates the cuprizone-induced white matter pathology in the brain of
C57BL/6 mouse. Schizophr Res (2008) 106:182–91. doi:10.1016/j.schres.2008.
09.013
81. Garver DL, Holcomb JA, Christensen JD. Compromised myelin integrity
during psychosis with repair during remission in drug-responding schiz-
ophrenia. Int J Neuropsychopharmacol (2008) 11:49–61. doi:10.1017/
S1461145707007730
82. Bartzokis G, Lu PH, Stewart SB, Oluwadara B, Lucas AJ, Pantages J, et al. In vivo
evidence of differential impact of typical and atypical antipsychotics on intra-
cortical myelin in adults with schizophrenia. Schizophr Res (2009) 113:322–31.
doi:10.1016/j.schres.2009.06.014
83. Ferno J, Raeder MB, Vik-Mo AO, Skrede S, Glambek M, Tronstad KJ, et al.
Antipsychotic drugs activate SREBP-regulated expression of lipid biosynthetic
genes in cultured human glioma cells: a novel mechanism of action? Pharma-
cogenomics J (2005) 5:298–304. doi:10.1038/sj.tpj.6500323
84. Ferno J, Skrede S, Vik-Mo A, Havik B, Steen V. Drug-induced activation of
SREBP-controlled lipogenic gene expression in CNS-related cell lines: marked
differences between various antipsychotic drugs. BMC Neurosci (2006) 7:69.
doi:10.1186/1471-2202-7-69
85. Skrede S, Fernø J, Vázquez MJ, Fjær S, Pavlin T, Lunder N, et al. Olanzapine,
but not aripiprazole, weight-independently elevates serum triglycerides and
activates lipogenic gene expression in female rats. Int J Neuropsychopharmacol
(2012) 15:163–79. doi:10.1017/S1461145711001271
86. Leucht S, Cipriani A, Spineli L, Mavridis D, Örey D, Richter F, et al. Com-
parative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia:
a multiple-treatments meta-analysis. Lancet (2013) 382:951–62. doi:10.1016/
S0140-6736(13)60733-3
87. Procyshyn RM, Wasan KM, Thornton AE, Barr AM, Chen EY, Pomarol-Clotet
E, et al. Changes in serum lipids, independent of weight, are associated with
changes in symptoms during long-term clozapine treatment. J Psychiatry Neu-
rosci (2007) 32:331–8.
88. Lally J, Gallagher A, Bainbridge E, Avalos G, Ahmed M, McDonald C. Increases
in triglyceride levels are associated with clinical response to clozapine treat-
ment. J Psychopharmacol (2013) 27:401–3. doi:10.1177/0269881112472568
89. Amminger GP, Schafer MR, Papageorgiou K, Klier CM, Cotton SM, Harrigan
SM, et al. Long-chain omega-3 fatty acids for indicated prevention of psychotic
disorders: a randomized, placebo-controlled trial. Arch Gen Psychiatry (2010)
67:146–54. doi:10.1001/archgenpsychiatry.2009.192
90. Peters BD, Machielsen MW, Hoen WP, Caan MW, Malhotra AK, Szeszko PR,
et al. Polyunsaturated fatty acid concentration predicts myelin integrity in
www.frontiersin.org February 2014 | Volume 5 | Article 11 | 11
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Kroken et al. A critical review of pro-cognitive drug targets
early-phase psychosis. Schizophr Bull (2013) 39:830–8. doi:10.1093/schbul/
sbs089
91. Kaddurah-Daouk R, McEvoy J, Baillie RA, Lee D, Yao JK, Doraiswamy PM,
et al. Metabolomic mapping of atypical antipsychotic effects in schizophrenia.
Mol Psychiatry (2007) 12:934–45. doi:10.1038/sj.mp.4002000
92. Yao J, Keshavan M. Antioxidants, redox signaling, and pathophysiology in
schizophrenia: an integrative view. Antioxid Redox Signal (2011) 15:2011–35.
doi:10.1089/ars.2010.3603
93. Zhang XY, Chen DC, Xiu MH, Tang W, Zhang F, Liu L, et al. Plasma total
antioxidant status and cognitive impairments in schizophrenia. Schizophr Res
(2012) 139:66–72. doi:10.1016/j.schres.2012.04.009
94. Meyer U, Schwarz MJ, Muller N. Inflammatory processes in schizophre-
nia: a promising neuroimmunological target for the treatment of nega-
tive/cognitive symptoms and beyond. Pharmacol Ther (2011) 132:96–110.
doi:10.1016/j.pharmthera.2011.06.003
95. Doorduin J, de Vries EF, Willemsen AT, de Groot JC, Dierckx RA, Klein HC.
Neuroinflammation in schizophrenia-related psychosis: a PET study. J Nucl
Med (2009) 50:1801–7. doi:10.2967/jnumed.109.066647
96. Ripke S, Sanders A, Kendler K, Levinson D, Sklar P, Holmans P, et al. Genome-
wide association study identifies five new schizophrenia loci. Nat Genet (2011)
43:969–76. doi:10.1038/ng.940
97. Debnath M, Cannon DM, Venkatasubramanian G. Variation in the major his-
tocompatibility complex [MHC] gene family in schizophrenia: associations
and functional implications. Prog Neuropsychopharmacol Biol Psychiatry (2013)
42:49–62. doi:10.1016/j.pnpbp.2012.07.009
98. Pickard B. Progress in defining the biological causes of schizophrenia. Expert
Rev Mol Med (2011) 13:e25. doi:10.1017/S1462399411001955
99. Sequeira PA, Martin MV, Vawter MP. The first decade and beyond of transcrip-
tional profiling in schizophrenia. Neurobiol Dis (2012) 45:23–36. doi:10.1016/
j.nbd.2011.03.001
100. Kayser M, Dalmau J. The emerging link between autoimmune disorders and
neuropsychiatric disease. J Neuropsychiatry Clin Neurosci (2011) 23:90–97.
doi:10.1176/appi.neuropsych.23.1.90
101. Dalmau J, Gleichman AJ, Hughes EG, Rossi JE, Peng X, Lai M, et al. Anti-
NMDA-receptor encephalitis: case series and analysis of the effects of antibod-
ies. Lancet Neurol (2008) 7:1091–8. doi:10.1016/S1474-4422(08)70224-2
102. American College of Rheumatology. The American College of Rheuma-
tology nomenclature and case definitions for neuropsychiatric lupus syn-
dromes. Arthritis Rheum (1999) 42:599–608. doi:10.1002/1529-0131(199904)
42:4<599::AID-ANR2>3.0.CO;2-F
103. Noto C, Gadelha A, Belangero SI, Spindola LM, Rocha NP, de Miranda AS, et al.
Circulating levels of sTNFR1 as a marker of severe clinical course in schizo-
phrenia. J Psychiatr Res (2013) 47:467–71. doi:10.1016/j.jpsychires.2012.12.010
104. Dean B. Understanding the role of inflammatory-related pathways in the
pathophysiology and treatment of psychiatric disorders: evidence from human
peripheral studies and CNS studies. Int J Neuropsychopharmacol (2011)
14:997–1012. doi:10.1017/S1461145710001410
105. Meyer U. Anti-inflammatory signaling in schizophrenia. Brain Behav Immun
(2011) 25:1507–18. doi:10.1016/j.bbi.2011.05.014
106. Miller B, Buckley P, Seabolt W, Mellor A, Kirkpatrick B. Meta-analysis of
cytokine alterations in schizophrenia: clinical status and antipsychotic effects.
Biol Psychiatry (2011) 70:663–671. doi:10.1016/j.biopsych.2011.04.013
107. Fineberg AM, Ellman LM. Inflammatory cytokines and neurological and neu-
rocognitive alterations in the course of schizophrenia. Biol Psychiatry (2013)
73:951–66. doi:10.1016/j.biopsych.2013.01.001
108. Drexhage RC, Knijff EM, Padmos RC, Heul-Nieuwenhuijzen LV, Beumer W,
Versnel MA, et al. The mononuclear phagocyte system and its cytokine inflam-
matory networks in schizophrenia and bipolar disorder. Expert Rev Neurother
(2009) 10:59–76. doi:10.1586/ern.09.144
109. Hope S, Melle I, Aukrust P, Steen NE, Birkenaes AB, Lorentzen S, et al. Sim-
ilar immune profile in bipolar disorder and schizophrenia: selective increase
in soluble tumor necrosis factor receptor I and von Willebrand factor. Bipolar
Disord (2009) 11:726–34. doi:10.1111/j.1399-5618.2009.00757.x
110. Potvin S, Stip E, Sepehry A, Gendron A, Bah R, Kouassi E. Inflammatory
cytokine alterations in schizophrenia: a systematic quantitative review. Biol
Psychiatry (2008) 63:801–808. doi:10.1016/j.biopsych.2007.09.024
111. Anthony DC, Pitossi FJ. Special issue commentary: the changing face of inflam-
mation in the brain. Mol Cell Neurosci (2013) 53:1–5. doi:10.1016/j.mcn.2012.
11.005
112. Beumer W, Gibney SM, Drexhage RC, Pont-Lezica L, Doorduin J, Klein
HC, et al. The immune theory of psychiatric diseases: a key role for acti-
vated microglia and circulating monocytes. J Leukoc Biol (2012) 92:959–75.
doi:10.1189/jlb.0212100
113. van Berckel BN, Bossong MG, Boellaard R, Kloet R, Schuitemaker A, Caspers
E, et al. Microglia activation in recent-onset schizophrenia: a quantitative (R)-
[11C]PK11195 Positron Emission Tomography Study. Biol Psychiatry (2008)
64:820–2. doi:10.1016/j.biopsych.2008.04.025
114. Pasternak O, Sochen N, Gur Y, Intrator N, Assaf Y. Free water elimina-
tion and mapping from diffusion MRI. Magn Reson Med (2009) 62:717–30.
doi:10.1002/mrm.22055
115. Pasternak O, Westin C, Bouix S, Seidman L, Goldstein J, Woo T, et al. Exces-
sive extracellular volume reveals a neurodegenerative pattern in schizophrenia
onset. J Neurosci (2012) 32(48):17365–72. doi:10.1523/JNEUROSCI.2904-12.
2012
116. Steiner J, Bogerts B, Sarnyai Z, Walter M, Gos T, Bernstein H-G, et al. Bridg-
ing the gap between the immune and glutamate hypotheses of schizophre-
nia and major depression: potential role of glial NMDA receptor modulators
and impaired blood-brain barrier integrity. World J Biol Psychiatry (2012)
13:482–92. doi:10.3109/15622975.2011.583941
117. Erhardt S, Blennow K, Nordin C, Skogh E, Lindström LH, Engberg G.
Kynurenic acid levels are elevated in the cerebrospinal fluid of patients with
schizophrenia. Neurosci Lett (2001) 313:96–8. doi:10.1016/S0304-3940(01)
02242-X
118. Schwarcz R, Rassoulpour A, Wu H-Q, Medoff D, Tamminga CA, Roberts RC.
Increased cortical kynurenate content in schizophrenia. Biol Psychiatry (2001)
50:521–30. doi:10.1016/S0006-3223(01)01078-2
119. Schwarcz R, Bruno JP, Muchowski PJ,Wu H-Q. Kynurenines in the mammalian
brain: when physiology meets pathology. Nat Rev Neurosci (2012) 13:465–77.
doi:10.1038/nrn3257
120. Erhardt S, Schwieler L, Emanuelsson C, Geyer M. Endogenous kynurenic acid
disrupts prepulse inhibition. Biol Psychiatry (2004) 56:255–60. doi:10.1016/j.
biopsych.2004.06.006
121. Stone TW, Darlington LG. The kynurenine pathway as a therapeutic tar-
get in cognitive and neurodegenerative disorders. Br J Pharmacol (2013)
169:1211–27. doi:10.1111/bph.12230
122. Wonodi I, Schwarcz R. Cortical kynurenine pathway metabolism: a novel target
for cognitive enhancement in schizophrenia. Schizophr Bull (2010) 36:211–8.
doi:10.1093/schbul/sbq002
123. Baran H, Kepplinger B. Cerebrolysin lowers kynurenic acid formation – an
in vitro study. Eur Neuropsychopharmacol (2009) 19:161–8. doi:10.1016/j.
euroneuro.2008.09.003
124. Shifu X, Haibo X, Guanjun L, Chengmei Y, Xia L, Chao C, et al. Therapeu-
tic effects of cerebrolysin added to risperidone in patients with schizophrenia
dominated by negative symptoms. Aust N Z J Psychiatry (2012) 46:153–60.
doi:10.1177/0004867411433213
125. Thome J, Doppler E. Safety profile of cerebrolysin: clinical experience from
dementia and stroke trials. Drugs Today (2012) 48(Suppl A):63–9. doi:10.1358/
dot.2012.48(Suppl.A).1739724
126. Alvarez XA, Cacabelos R, Sampedro C, Aleixandre M, Linares C, Granizo E,
et al. Efficacy and safety of cerebrolysin in moderate to moderately severe
Alzheimer’s disease: results of a randomized, double-blind, controlled trial
investigating three dosages of cerebrolysin. Eur J Neurol (2011) 18:59–68.
doi:10.1111/j.1468-1331.2010.03092.x
127. Plosker G, Gauthier S. Cerebrolysin. Drugs Aging (2009) 26:893–915. doi:10.
2165/11203320-000000000-00000
128. Chen C-C, Wei S-T, Tsaia S-C, Chen X-X, Cho D-Y. Cerebrolysin enhances cog-
nitive recovery of mild traumatic brain injury patients: double-blind, placebo-
controlled, randomized study. Br J Neurosurg (2013) 27:803–7. doi:10.3109/
02688697.2013.793287
129. Baran H, Kepplinger B. d-Cycloserine lowers kynurenic acid formation –
new mechanism of action. Eur Neuropsychopharmacol (2013). doi:10.1016/j.
euroneuro.2013.10.006
130. Goff DC. D-cycloserine: an evolving role in learning and neuroplasticity in
schizophrenia. Schizophr Bull (2012) 38:936–41. doi:10.1093/schbul/sbs012
131. Fogal B, Hewett SJ. Interleukin-1β: a bridge between inflammation and excito-
toxicity? J Neurochem (2008) 106:1–23. doi:10.1111/j.1471-4159.2008.05315.x
132. Gardoni F, Boraso M, Zianni E, Corsini E, Galli C, Cattabeni F, et al. Distrib-
ution of interleukin-1 receptor complex at the synaptic membrane driven by
Frontiers in Psychiatry | Schizophrenia February 2014 | Volume 5 | Article 11 | 12
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Kroken et al. A critical review of pro-cognitive drug targets
interleukin-1beta and NMDA stimulation. J Neuroinflammation (2011) 8:14.
doi:10.1186/1742-2094-8-14
133. Chew LJ, Fusar-Poli P, Schmitz T. Oligodendroglial alterations and the role
of microglia in white matter injury: relevance to schizophrenia. Dev Neurosci
(2013) 35:102–29. doi:10.1159/000346157
134. Schmitz T, Chew L-J. Cytokines and myelination in the central nervous system.
ScientificWorldJournal (2008) 8:1119–47. doi:10.1100/tsw.2008.140
135. Najjar S, Pearlman D, Alper K, Najjar A, Devinsky O. Neuroinflammation and
psychiatric illness. J Neuroinflammation (2013) 1(10):43. doi:10.1186/1742-
2094-10-43
136. Schroeter ML, Abdul-Khaliq H, Krebs M, Diefenbacher A, Blasig IE. Neuron-
specific enolase is unaltered whereas S100B is elevated in serum of patients
with schizophrenia – original research and meta-analysis. Psychiatry Res (2009)
167:66–72. doi:10.1016/j.psychres.2008.01.002
137. Kerschensteiner M, Stadelmann C, Dechant G, Wekerle H, Hohlfeld R. Neu-
rotrophic cross-talk between the nervous and immune systems: implications
for neurological diseases. Ann Neurol (2003) 53:292–304. doi:10.1002/ana.
10446
138. Nurjono M, Lee J, Chong SA. A review of brain-derived neurotrophic factor as
a candidate biomarker in schizophrenia. Clin Psychopharmacol Neurosci (2012)
10:61–70. doi:10.9758/cpn.2012.10.2.61
139. Nieto R, Kukuljan M, Silva H. BDNF and schizophrenia: from neurodevelop-
ment to neuronal plasticity, learning, and memory. Front Psychiatry (2013)
4:45. doi:10.3389/fpsyt.2013.00045
140. Goff DC. Future perspectives on the treatment of cognitive deficits and
negative symptoms in schizophrenia. World Psychiatry (2013) 12:99–107.
doi:10.1002/wps.20026
141. Monji A, Kato TA, Mizoguchi Y, Horikawa H, Seki Y, Kasai M, et al. Neuroin-
flammation in schizophrenia especially focused on the role of microglia. Prog
Neuropsychopharmacol Biol Psychiatry (2013) 42:115–21. doi:10.1016/j.pnpbp.
2011.12.002
142. Ceresoli-Borroni G, Rassoulpour A, Wu HQ, Guidetti P, Schwarcz R. Chronic
neuroleptic treatment reduces endogenous kynurenic acid levels in rat brain.
J Neural Transm (2006) 113:1355–65. doi:10.1007/s00702-005-0432-z
143. Nitta M, Kishimoto T, Müller N,Weiser M, Davidson M, Kane JM, et al. Adjunc-
tive use of nonsteroidal anti-inflammatory drugs for schizophrenia: a meta-
analytic investigation of randomized controlled trials. Schizophr Bull (2013)
39(6):1230–41. doi:10.1093/schbul/sbt070
144. Sommer IE, van Westrhenen R, Begemann MJ, de Witte LD, Leucht S,
Kahn RS. Efficacy of anti-inflammatory agents to improve symptoms in
patients with schizophrenia: an update. Schizophr Bull (2013) 40(1):181–91.
doi:10.1093/schbul/sbt139
145. Muller N, Riedel M, Schwarz MJ, Engel RR. Clinical effects of COX-2 inhibitors
on cognition in schizophrenia. Eur Arch Psychiatry Clin Neurosci (2005)
255:149–51. doi:10.1007/s00406-004-0548-4
146. Sirén A-L, Faßhauer T, Bartels C, Ehrenreich H. Therapeutic potential of ery-
thropoietin and its structural or functional variants in the nervous system.
Neurotherapeutics (2009) 6:108–27. doi:10.1016/j.nurt.2008.10.041
147. Ehrenreich H, Hinze-Selch D, Stawicki S, Aust C, Knolle-Veentjer S, Wilms S,
et al. Improvement of cognitive functions in chronic schizophrenic patients
by recombinant human erythropoietin. Mol Psychiatry (2007) 12:206–20.
doi:10.1038/sj.mp.4001907
148. Wustenberg T, Begemann M, Bartels C, Gefeller O, Stawicki S, Hinze-Selch D,
et al. Recombinant human erythropoietin delays loss of gray matter in chronic
schizophrenia. Mol Psychiatry (2011) 16:26–36. doi:10.1038/mp.2010.51
149. Fond G, Macgregor A, Attal J, Larue A, Brittner M, Ducasse D, et al. Treating
patients with schizophrenia deficit with erythropoietin? Psychiatry Clin Neu-
rosci (2012) 66:375–82. doi:10.1111/j.1440-1819.2012.02359.x
150. Jang W, Park J, Shin KJ, Kim J-S, Kim JS, Youn J, et al. Safety and efficacy
of recombinant human erythropoietin treatment of non-motor symptoms in
Parkinson’s disease. J Neurol Sci (2013). doi:10.1016/j.jns.2013.11.015
151. Sargin D, Friedrichs H, El-Kordi A, Ehrenreich H. Erythropoietin as neuro-
protective and neuroregenerative treatment strategy: comprehensive overview
of 12 years of preclinical and clinical research. Best Pract Res Clin Anaesthesiol
(2010) 24:573–94. doi:10.1016/j.bpa.2010.10.005
152. Domercq M, Matute C. Neuroprotection by tetracyclines. Trends Pharmacol
Sci (2004) 25:609–12. doi:10.1016/j.tips.2004.10.001
153. Levkovitz Y, Mendlovich S, Riwkes S, Braw Y, Levkovitch-Verbin H, Gal G, et al.
A double-blind, randomized study of minocycline for the treatment of negative
and cognitive symptoms in early-phase schizophrenia. J Clin Psychiatry (2010)
71:138–149. doi:10.4088/JCP.08m04666yel
154. Chaudhry IB, Hallak J, Husain N, Minhas F, Stirling J, Richardson P, et al.
Minocycline benefits negative symptoms in early schizophrenia: a randomised
double-blind placebo-controlled clinical trial in patients on standard treat-
ment. J Psychopharmacol (2012) 26:1185–93. doi:10.1177/0269881112444941
155. Kay SR, Fiszbein A, Opler LA. The Positive and Negative Syndrome Scale
(PANSS) for schizophrenia. Schizophr Bull (1987) 13:261–76. doi:10.1093/
schbul/13.2.261
156. Overall J, Gorham D. The Brief Psychiatric Rating Scale. Psychol Rep (1962)
10:799–812. doi:10.2466/pr0.1962.10.3.799
Conflict of Interest Statement: The authors declare that the research was conducted
in the absence of any commercial or financial relationships that could be construed
as a potential conflict of interest.
Received: 01 October 2013; accepted: 20 January 2014; published online: 04 February
2014.
Citation: Kroken RA, Løberg E-M, Drønen T, Grüner R, Hugdahl K, Kompus K,
Skrede S and Johnsen E (2014) A critical review of pro-cognitive drug targets in psy-
chosis: convergence on myelination and inflammation. Front. Psychiatry 5:11. doi:
10.3389/fpsyt.2014.00011
This article was submitted to Schizophrenia, a section of the journal Frontiers in
Psychiatry.
Copyright © 2014 Kroken, Løberg , Drønen, Grüner, Hugdahl, Kompus, Skrede and
Johnsen. This is an open-access article distributed under the terms of the Creative
Commons Attribution License (CC BY). The use, distribution or reproduction in other
forums is permitted, provided the original author(s) or licensor are credited and that
the original publication in this journal is cited, in accordance with accepted academic
practice. No use, distribution or reproduction is permitted which does not comply with
these terms.
www.frontiersin.org February 2014 | Volume 5 | Article 11 | 13
